Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

CDC Science Clips
COVID-10 GPH

Last data update: Jan 21, 2025. (Total: 48615 publications since 2009)
(Author names in bold with hyperlink are CDC authors)
Filtered By:
Order By:
Records 1-1 (of 1 Records)
Query Trace: Matlhaba O[original query]
CD4+ cell count, viral load, and drug resistance patterns among heterosexual breakthrough HIV infections in a study of oral preexposure prophylaxis
Chirwa LI , Johnson JA , Niska RW , Segolodi TM , Henderson FL , Rose CE , Li JF , Thigpen MC , Matlhaba O , Paxton LA , Brooks JT .
AIDS 2013 28 (2) 223-6 type

We examined CD4 cell count and plasma viral load patterns among Botswana TDF/FTC Oral HIV Prophylaxis Trial (TDF2 study) participants who seroconverted, comparing participants assigned to receive tenofovir/emtricitabine with participants assigned to receive placebo. We also evaluated for antiretroviral drug resistance among the breakthrough HIV infections. Among nine seroconverters assigned to tenofovir/emtricitabine and 24 to placebo, there were no significant differences in their CD4 cell count or viral load profiles over time. Of the four participants who seroconverted on-study while receiving tenofovir/emtricitabine, none became infected as a result of drug-resistant HIV; moreover, no resistance mutations emerged following seroconversion.
TOP